Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).
Stephen V. Liu(Georgetown University), Hossein Borghaei(Fox Chase Cancer Center), Hirva Mamdani(Wayne State University), Ari M. Vanderwalde(West Cancer Center), W. Michael Korn(Itasca Community College), Alexander I. Spira(Virginia Cancer Specialists), Sachin Gopalkrishna Pai(USA Mitchell Cancer Institute), Misako Nagasaka(University of California, Irvine), Edward S. Kim(The University of Texas MD Anderson Cancer Center), Jorge J. Nieva(University of Southern California), Yasmine Baca(Caris Life Sciences (United States)), Mark A. Socinski(Florida Hospital Cancer Institute), Joanne Xiu(Caris Life Sciences (United States)), Chukwuemeka Ikpeazu(Sylvester Comprehensive Cancer Center), Chul Kim(Georgetown University), Antoinette J. Wozniak(Wayne State University), Gilberto Lopes(University of Miami), Julia Judd(Palmetto Hematology Oncology), Luis E. Raez(Florida International University)
Cited by 5
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k